Mark Jeffrey Delong Sells 363 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Stock

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) insider Mark Jeffrey Delong sold 363 shares of the business’s stock in a transaction that occurred on Tuesday, February 11th. The shares were sold at an average price of $28.54, for a total value of $10,360.02. Following the completion of the sale, the insider now owns 83,945 shares of the company’s stock, valued at $2,395,790.30. This trade represents a 0.43 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.

Apellis Pharmaceuticals Stock Performance

APLS stock opened at $27.46 on Friday. The company has a 50-day simple moving average of $31.45 and a 200 day simple moving average of $32.30. The company has a market capitalization of $3.42 billion, a P/E ratio of -13.53 and a beta of 0.96. The company has a quick ratio of 3.73, a current ratio of 4.36 and a debt-to-equity ratio of 1.91. Apellis Pharmaceuticals, Inc. has a fifty-two week low of $24.34 and a fifty-two week high of $71.90.

Institutional Trading of Apellis Pharmaceuticals

Institutional investors have recently made changes to their positions in the stock. KBC Group NV increased its stake in shares of Apellis Pharmaceuticals by 34.8% during the third quarter. KBC Group NV now owns 2,632 shares of the company’s stock valued at $76,000 after acquiring an additional 679 shares during the period. Xponance Inc. boosted its stake in Apellis Pharmaceuticals by 5.6% during the 4th quarter. Xponance Inc. now owns 14,072 shares of the company’s stock valued at $449,000 after purchasing an additional 749 shares in the last quarter. EverSource Wealth Advisors LLC increased its position in shares of Apellis Pharmaceuticals by 2,707.1% during the 4th quarter. EverSource Wealth Advisors LLC now owns 786 shares of the company’s stock valued at $25,000 after purchasing an additional 758 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Apellis Pharmaceuticals by 21.6% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,404 shares of the company’s stock worth $130,000 after buying an additional 781 shares in the last quarter. Finally, Signaturefd LLC lifted its holdings in shares of Apellis Pharmaceuticals by 357.2% in the fourth quarter. Signaturefd LLC now owns 1,175 shares of the company’s stock valued at $37,000 after buying an additional 918 shares during the period. 96.29% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

APLS has been the subject of several recent research reports. The Goldman Sachs Group lowered shares of Apellis Pharmaceuticals from a “buy” rating to a “neutral” rating and set a $36.00 target price for the company. in a research note on Tuesday, December 17th. Citigroup lowered their price objective on shares of Apellis Pharmaceuticals from $63.00 to $51.00 and set a “buy” rating for the company in a research report on Wednesday, November 6th. Morgan Stanley started coverage on shares of Apellis Pharmaceuticals in a report on Thursday, November 21st. They issued an “equal weight” rating and a $31.00 target price on the stock. Mizuho lowered their target price on Apellis Pharmaceuticals from $39.00 to $38.00 and set a “neutral” rating for the company in a report on Thursday, October 24th. Finally, Robert W. Baird dropped their price target on Apellis Pharmaceuticals from $92.00 to $55.00 and set an “outperform” rating on the stock in a research report on Thursday, November 7th. Eight equities research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $46.71.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).